These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18364659)

  • 21. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare.
    Calfee DP
    Curr Opin Infect Dis; 2012 Aug; 25(4):385-94. PubMed ID: 22614523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging serious Gram-positive infections.
    Menichetti F
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
    Jones RN
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
    Tverdek FP; Crank CW; Segreti J
    Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Gram-positive antibiotics: better than vancomycin?
    van Hal SJ; Paterson DL
    Curr Opin Infect Dis; 2011 Dec; 24(6):515-20. PubMed ID: 21844804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections caused by Gram-positive bacteria: a review of the global challenge.
    Woodford N; Livermore DM
    J Infect; 2009 Sep; 59 Suppl 1():S4-16. PubMed ID: 19766888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA; Koch KM; Dowzicky MJ
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics.
    Oksuz L; Gurler N
    J Infect Dev Ctries; 2013 Nov; 7(11):825-31. PubMed ID: 24240040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activity of daptomycin against VRE and MRSA strains].
    Aktaş G; Derbentli S
    Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance mechanisms of gram-positive bacteria.
    Berger-Bächi B
    Int J Med Microbiol; 2002 Jun; 292(1):27-35. PubMed ID: 12139425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
    Nailor MD; Sobel JD
    Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.
    Mauldin PD; Salgado CD; Durkalski VL; Bosso JA
    Ann Pharmacother; 2008 Mar; 42(3):317-26. PubMed ID: 18285560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.